The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice

Journal of Lipid Research

Volumn 43, Issue 9, 2002, Pages 1458-1463

  Riddle, Tara M ^a   Schildmeyer, Nicholas M ^a   Phan, Cam ^a   Fichtenbaum, Carl J ^a   Hui, David Y ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Anti retroviral therapy; Apolipoprotein B; High fat diet; Very low density lipoprotein synthesis

Indexed keywords

APOLIPOPROTEIN B; DIACYLGLYCEROL ACYLTRANSFERASE; LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; STEROL REGULATORY ELEMENT BINDING PROTEIN; TYLOXAPOL; VERY LOW DENSITY LIPOPROTEIN; ACYLTRANSFERASE; APOLIPOPROTEIN B100; DGAT1 PROTEIN, MOUSE; MESSENGER RNA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN TRIGLYCERIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HYPERLIPIDEMIA; LIPID DIET; LIPOPROTEIN SECRETION; LIPOPROTEIN SYNTHESIS; LOW FAT DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; DIET; ENZYMOLOGY; FAT INTAKE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; SECRETION;

ACYLTRANSFERASES; ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; DIACYLGLYCEROL O-ACYLTRANSFERASE; DIET; DIETARY FATS; HIV; HIV PROTEASE INHIBITORS; LIPOPROTEINS; LIPOPROTEINS, VLDL; LIVER; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; RITONAVIR; RNA, MESSENGER; TRIGLYCERIDES;

EID: 0036737581     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M200129-JLR200     Document Type: Article

References (26)

1. Palella, F. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity, and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med. 338: 853-860.
2. Hogg, R. S., B. Yip, C. Kully, K.J. Craib, M. V. O'Shaughnessy, M. T. Schechter, and J. S. Montaner. 1999. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 160:659-665.
3. Debouck, C. 1992. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses. 8: 153-164.
4. Carr, A., K. Samaras, D.J. Chisholm, and D. A. Cooper. 1998. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 351: 1881-1883.
5. Carr, A., K. Samaras, S, Burton, M. Law, J. Freund, D.J. Chisholm, and D. A. Cooper. 1998. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12: F51-F58.
6. Roth, V. R., S. Kravcik, and J. B. Angel. 1998. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin. Infect. Dis. 27: 65-67.
7. Safrin, S., and C. Grunfeld. 1999. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 13: 2493-2505.
8. Mulligan, K., C. Grunfeld, V. W. Tai, H. Algren, M. Pang, D. N. Chernoff, J. C. Lo, and M. Schambelan. 2000. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 23: 35-43.
9. Noor, M. A., J. C. Lo, K. Mulligan, J. M. Schwarz, R. A. Halvorsen, M. Schambelan, and C. Grunfeld. 2001. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 15: F11-F18.
10. Periard, D., A. Telenti, P. Sudre, J. J. Cheseaux, P. Halfon, M. J. Reymond, S. M. Marcovina, M. P. Glauser, P. Nicod, R. Darioli, and V. Mooser. 1999. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 100: 700-705.
11. Purnell, J. Q., A. Zambon, R. H. Knopp, D. J. Pizzuti, R. Achari, J. M. Leonard, C. Locke, and J. D. Brunzell. 2000. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 14: 51-57.
12. Riddle, T. M., D. G. Kuhel, L. A. Woollett, C. J. Fichtenbaum, and D. Y. Hui. 2001. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 276: 37514-37519.
13. Nerurkar, P. V., C. M. Shikuma, and V. R. Nerurkar. 2001. Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly active antiretroviral therapy (HAART)-associated lipodystrophy. Clin. Biochem. 34: 519-529.
14. Dixon, J. L., and H. N. Ginsberg. 1993. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J. Lipid Res. 34: 167-179.
15. Yao, Z., K. Tran, and R. S. McLeod. 1997. Intra-cellular degradation of newly synthesized apolipoprotein B. J. Lipid Res. 38: 1937-1953.
16. Liao, W., S. C. J. Yeung, and L. Chan. 1998. Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full length apolipoprotein B after translocation into endoplasmic reticulum. J. Biol. Chem. 273: 27225-27230.
17. Davis, R. A. 1999. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim. Biophys. Acta. 1440: 1-31.
18. Liang, J. S., O. Distler, D. A. Cooper, H. Jamil, R.J. Deckelbaum, H. N. Ginsberg, and S. L. Sturley. 2001. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med. 7: 1327-1331.
19. Nagata, Y., and D. B. Zilversmit. 1987. Blockade of intestinal lipoprotein clearance in rabbits injected with Triton WR 1339-ethyl oleate. J. Lipid Res. 28: 684-692.
20. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
21. Lowry, O. H., N. J. Rosebrough, A. L. Far, and R. J. Randall. 1951. Protein measurement with the Folin-phenol reagent. J. Biol. Chem. 193: 265-275.
22. Redgrave, T. G., and R. C. Maranhao. 1985. Metabolism of proteinfree lipid emulsion models of chylomicrons in rats. Biochim. Biophys. Acta. 835: 104-112.
23. Redgrave, T. G., G. G. Vassiliou, and M. J. Callow. 1987. Cholesterol is necessary for triacylglycerol-phospholipid emulsions to mimic the metabolism of lipoproteins. Biochim. Biophys. Acta. 921: 154-157.
24. Horton, J. D., Y. Bashmakov, I. Shimomura, and H. Shimano. 1998. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl. Acad. Sci. USA. 95: 5987-5992.
25. Schmitz, M., G. M. Michl, R. Walli, J. Bogner, A. Bedynek, D. Seidel, F. D. Goebel, and T. Demant. 2001. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J. Acquir. Immune Defic. Syndr. 26: 225-235.
26. Grunfeld, C., M. Pang, W. Doerrler, J. K. Shigenaga, P. Jensen, and K. R. Feingold. 1992. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74: 1045-1052.